News & Updates

Mindfulness and cognitive behavioural therapy (CBT) appear beneficial for prostate cancer survivors and their partners who are dealing with sexual dysfunction, a study has shown.

For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.

Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.

In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.

Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.

Patients with bladder cancer who underwent radical cystectomy may benefit from the use of smartphones and wearable technology to monitor their symptoms as well as biometric data, according to a recent study.

In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.

In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.